- Home
- AENT vs NMRA Comparison
AENT vs NMRA Comparison
Compare AENT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- NMRA
- Stock Information
- Founded
- AENT 1990
- NMRA 2019
- Country
- AENT United States
- NMRA United States
- Employees
- AENT N/A
- NMRA N/A
- Industry
- AENT Durable Goods
- NMRA
- Sector
- AENT Consumer Discretionary
- NMRA
- Exchange
- AENT Nasdaq
- NMRA Nasdaq
- Market Cap
- AENT 290.3M
- NMRA 287.6M
- IPO Year
- AENT N/A
- NMRA 2023
- Fundamental
- Price
- AENT $3.81
- NMRA $1.18
- Analyst Decision
- AENT
- NMRA Buy
- Analyst Count
- AENT 0
- NMRA 8
- Target Price
- AENT N/A
- NMRA $10.14
- AVG Volume (30 Days)
- AENT 85.0K
- NMRA 1.4M
- Earning Date
- AENT 05-08-2025
- NMRA 03-03-2025
- Dividend Yield
- AENT N/A
- NMRA N/A
- EPS Growth
- AENT N/A
- NMRA N/A
- EPS
- AENT 0.13
- NMRA N/A
- Revenue
- AENT $1,070,804,000.00
- NMRA N/A
- Revenue This Year
- AENT $4.77
- NMRA N/A
- Revenue Next Year
- AENT N/A
- NMRA N/A
- P/E Ratio
- AENT $28.14
- NMRA N/A
- Revenue Growth
- AENT N/A
- NMRA N/A
- 52 Week Low
- AENT $1.10
- NMRA $1.16
- 52 Week High
- AENT $11.57
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- AENT 40.23
- NMRA 28.48
- Support Level
- AENT $3.17
- NMRA $1.26
- Resistance Level
- AENT $4.93
- NMRA $1.48
- Average True Range (ATR)
- AENT 0.47
- NMRA 0.13
- MACD
- AENT -0.00
- NMRA 0.08
- Stochastic Oscillator
- AENT 31.75
- NMRA 10.99
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.